Redx Pharma Plc (REDX.L)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Lisa Mary Whewell Anson | CEO & Executive Director | 608.13k | -- | 1968 |
| Mr. Peter J. Collum | Chief Financial Officer | -- | -- | -- |
| Dr. James Mead | Chief Operating Officer | 132.67k | -- | 1978 |
| Dr. Richard Armer | Chief Scientific Officer | -- | -- | -- |
| Dr. Karl Hard Ph.D. | Head of Investor Relations | -- | -- | 1962 |
| Ms. Claire Penelope Solk | General Counsel & Company Secretary | -- | -- | -- |
| Ms. Caitlin Pearson | Head of Communications | -- | -- | -- |
| Dr. Cliff Jones | Senior Vice President of Chemistry, DMPK & Intellectual Property | -- | -- | -- |
| Dr. Caroline Phillips | Senior Vice President of Biology | -- | -- | -- |
| Mr. Craig Tilston | Head of Development Operations | -- | -- | -- |
Redx Pharma Plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 101
Description
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Corporate Governance
Recent Events
Recent Events Information Not Available